Colon Cancer News
-
Exploring Biomarkers for Regorafenib Response in Metastatic Colorectal Cancer with the Precellys Evolution
Colorectal cancer affects the colon or rectum and is on the rise among young adults. Lifestyle factors like diet and physical inactivity may contribute to its incidence. Early detection through regular screenings is crucial for effective management. Awareness of symptoms and risk factors is essential for timely intervention. The 4th of February marks the World Cancer Day. In this publication, ...
-
Iterative Scopes Partners with One GI to Advance Gastrointestinal Care Through Artificial Intelligence
Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with One GI®, a gastroenterology management services organization (MSO), to bring its AI Recruitment (AIR) technology to One GI’s clinical research. Initially, One GI® will use AIR at Gastro One, one of One GI’s clinical research sites in Memphis, ...
-
Built In Honors Iterative Health in Its Esteemed 2023 Best Places To Work Awards
Built In today announced that Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, was honored in its 2023 Best Places To Work Awards. Specifically, the company earned a place on the list of Boston’s Best Midsize Places to Work. The annual awards program includes companies of all sizes, from startups to those in the enterprise, and honors both remote-first ...
-
Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced a clinical trial collaboration and supply agreement. This agreement covers the execution of a Phase 2 clinical trial to evaluate the novel combination of ...
-
Iterative Health Partners with Gastro Health to Accelerate Clinical Research in Gastroenterology Through Artificial Intelligence
Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with Gastro Health, a national leading medical group specializing in digestive and liver health, to bring its AI Recruitment (AIR) technology to Gastro Health’s practices. This strategic partnership will lay the groundwork for future collaborations by using AIR to aid ...
-
Iterative Health Named to the 2022 CB Insights’ Digital Health 150 List
Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, today announced that it has been named one of CB Insights’ top 150 companies in Digital Health for 2022, the second year in a row in which it has made this list. The Digital Health 150 is CB Insights’ annual ranking of the 150 most promising digital health startups in the world. Iterative Health was ...
-
Molecular Devices adds proprietary patient-derived organoid technology with acquisition of Cellesce
Molecular Devices, LLC., a leading provider of high-performance life science solutions, today announced the acquisition of Cellesce Ltd (“Cellesce”) which specializes in contract development and manufacturing of large scale patient-derived organoids (PDOs) for diverse applications, including drug screening. Drug efficacy and toxicity testing often rely on immortalized cell lines or ...
By Cellesce Ltd
-
Iterative Health Redefines Approach to Precision GI Care
Iterative Health, formerly known as Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, has announced a rebrand to reflect the company’s success in utilizing artificial intelligence (AI) to strengthen clinical research and augment clinical decision making within gastroenterology. In this new chapter, Iterative Health will continue to focus on its core ...
-
Cancer Treatment is the USA: Methods, Top Clinics, Cost, Financing Options
The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...
-
Iterative Scopes Receives FDA Clearance for AI-Assisted Polyp Detection Device SKOUT
Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions, announced today that SKOUT™ has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for adults undergoing colorectal cancer screening or surveillance. SKOUT, a real-time ...
-
Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer
Results from the primary analysis of the SUNLIGHT trial to be presented at an upcoming scientific conference Paris - September 12, 2022– Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the investigational combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in the primary endpoint of overall survival ...
-
Carina Biotech raises $7.5 million at first close with Tenmile as the cornerstone investor
Carina Biotech is extremely pleased to announce that it has raised $7.5 million at first close of its current funding round, welcoming on board new venture capital business Tenmile as the cornerstone investor together with strong support from existing investors. “We are delighted to welcome Tenmile as an investor in Carina Biotech with its commitment to accelerate high impact, cutting edge ...
-
SafeHeal appoints medical device industry veteran Chris Richardson as Chief Executive Officer
PARIS, France/Tampa, FL – July, 11, 2022 – SafeHeal™, a leading innovator in the field of digestive surgery and developer of the Colovac device, announced today the appointment of Chris Richardson as Chief Executive Officer (CEO), who assumes responsibilities immediately. Richardson has over 30 years of experience in the medical device industry, and an extensive ...
By SafeHeal
-
Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer
LONDON, June 27, 2022– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient has been dosed in the OBERTO 301 Phase 2 trial of PolyPEPI1018, the Company’s lead product candidate, in combination with atezolizumab, Roche’s ...
-
Check-Cap Ltd. (NASDAQ: CHEK) Announces Receipt of Extension to Meet the Nasdaq`s Minimum Bid Price Requirement
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), announces that onJune 22, 2022, it received a letter from The Nasdaq Stock Market LLC ...
-
Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference
The growing body of information regarding Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society’s annual conference in Denver, Colorado. During the conference, the Prostate Snap Oral I scientific session included two abstracts that were presented by The Cesium Advisory ...
By Isoray Inc.
-
Xilis Presents Data at ESMO 2021 Demonstrating Capabilities of MicroOrganoSphere Technology for Cancer Drug Screening
Data suggests MOS platform recapitulates primary tumor tissue heterogeneity, including genomic and transcriptomic features, and microenvironment, comprising immune and stromal components MOS can be used in the evaluation of cancer drug response for chemotherapies and immunotherapies in the research setting Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology ...
By XILIS, Inc.
-
Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits
Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - Combined company Senti Bio will be listed on the Nasdaq Global Market under ticker symbol "SNTI" - IND filings for preclinical oncology candidates SENTI-202 and SENTI-301 anticipated in 2023 - Senti Biosciences, Inc. ...
-
Xilis Announces Breast Cancer Oncologist Dr. Daniel F. Hayes to Join Clinical Advisory Board
Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that breast cancer oncologist Daniel F. Hayes, MD, FACP, FASCO, has joined the company’s Clinical Advisory Board (CAB). Dr. Hayes is a Professor of Internal Medicine, the Stuart B. Padnos Professor ...
By XILIS, Inc.
-
Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress
AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022 AFM13 combination with NK cells: Reported data at AACR 2022 showing a 100% objective response rate (ORR) and an increase in complete responses (CR) from 38%, reported in December, to 62% after a second cycle of therapy in 13 ...
By Affimed GmbH
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you